GSK buys long term partner Human Genome Science

Reuters have reported that GlaxoSmithKline is to acquire its long-time partner Human Genome Science for £1.92 billion pounds.

This new acquisition will fit in well with with GSK’s long-term strategy of delivering sustainable growth, simplifying GSK’s business model, enhancing R&D returns and deploying capital with discipline.

Also now they have the complete ownership of BENLYSTA, albiglutide and darapladib, GSK can simplify and optimize R&D, commercial and manufacturing operations to advance these products most effectively and efficiently while securing the full potential long-term value of the assets.

Sir Andrew Witty, Chief Executive Officer of GSK, said: “We are pleased to have reached a mutually beneficial agreement with HGS on friendly terms and believe the combination of GSK and HGS represents clear financial and strategic logic for both companies and our respective shareholders….This is a natural next step in our nearly 20-year relationship with HGS, and we look forward to working with HGS to integrate our businesses and to realizing the full value of BENLYSTA, albiglutide, and darapladib for the benefit of patients and our shareholders.”


Click here to see our latest clinical jobs in the UK and Europe

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in: company news, News
CK Logo in place of featured image